Executive leadership at Immix Biopharma.
Board of directors at Immix Biopharma.
Research analysts covering Immix Biopharma.
Recent press releases and 8-K filings for IMMX.
Ipsen Completes Acquisition of ImCheck Therapeutics
IMMX
M&A
New Projects/Investments
- Ipsen completed the acquisition of ImCheck Therapeutics, a private French biotechnology company, on December 15, 2025.
- This acquisition expands Ipsen's pipeline, particularly in next-generation immuno-oncology therapies.
- Ipsen is a global biopharmaceutical company focused on Oncology, Rare Disease, and Neuroscience.
Dec 15, 2025, 4:30 PM
Immix Biopharma Announces Underwritten Registered Offering of Common Stock and Pre-Funded Warrants
IMMX
- Immix Biopharma, Inc. entered into an underwriting agreement on December 7, 2025, for an underwritten registered offering of common stock and pre-funded warrants.
- The offering includes the sale of common stock and pre-funded warrants, with each pre-funded warrant having an exercise price of $0.01 per share.
- The company expects to receive approximately $93.7 million in net proceeds from this offering, which is anticipated to close on December 9, 2025.
- Detailed quantitative information regarding the offering is provided in the table below.
| Metric | Offering Details |
|---|---|
| Number of Shares of Common Stock Offered (Shares) | 19,117,646 |
| Price per Share of Common Stock ($USD) | $5.10 |
| Number of Pre-Funded Warrants Offered (Warrants) | 490,196 |
| Price per Pre-Funded Warrant ($USD) | $5.09 |
| Exercise Price per Pre-Funded Warrant ($USD) | $0.01 |
| Expected Net Proceeds to Company ($USD Millions) | $93.7 |
Dec 8, 2025, 10:30 PM
Immix Biopharma Reports Positive Phase 2 NXC-201 Results
IMMX
Product Launch
New Projects/Investments
- Immix Biopharma, Inc. (IMMX) announced positive Phase 2 NXC-201 results for relapsed/refractory AL Amyloidosis at ASH 2025, based on clinical data as of November 13, 2025.
- NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) by independent review committee, with the potential to increase to 95% based on minimum residual disease (MRD) negativity in bone marrow for four out of five pending patients.
- The company plans for the NEXICART-2 final readout and Biologics License Application (BLA) submission in 2026.
- NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) from the FDA and Orphan Drug Designation (ODD) by the US FDA and EU EMA.
Dec 8, 2025, 11:15 AM
Immix Biopharma Announces Pricing of $100 Million Offering
IMMX
New Projects/Investments
- Immix Biopharma priced an underwritten registered offering of 19,117,646 shares of common stock at $5.10 per share and 490,196 pre-funded warrants at $5.09 per warrant.
- The offering is expected to generate $100 million in gross proceeds and is anticipated to close around December 9, 2025.
- The net proceeds, combined with existing cash and a CIRM grant, are intended to fund NXC-201 development and extend the company's operational runway into mid-2027.
Dec 7, 2025, 11:20 PM
ImCheck Therapeutics Acquisition by Ipsen
IMMX
M&A
New Projects/Investments
Takeover Bid
- Ipsen has entered into a definitive agreement to acquire ImCheck Therapeutics, a French biotechnology company, for a closing purchase price of 350 million euros.
- The acquisition is primarily focused on ImCheck's lead clinical-stage program, ICT01, which is being developed for first-line acute myeloid leukemia (AML).
- ImCheck Therapeutics' shareholders are eligible to receive additional downstream payments contingent upon the achievement of regulatory and sales-based milestones, potentially bringing the total consideration to up to 1 billion euros.
- The transaction is expected to close by the end of Q1 2026, subject to customary closing conditions and regulatory approvals.
Oct 22, 2025, 5:00 AM
Immix Biopharma to Present NXC-201 Abstract at ASH 2025 Meeting
IMMX
New Projects/Investments
- Immix Biopharma will present an NXC-201 abstract at the American Society of Hematology (ASH) 67th Annual Meeting and Exposition from December 6-9, 2025, in Orlando, Florida.
- NXC-201, a BCMA-targeted CAR-T cell therapy for relapsed/refractory AL Amyloidosis, met its primary endpoint at interim results presented at ASCO 2025.
- The therapy has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by the FDA and EMA.
- The Amyloidosis market is expected to reach $6 billion in 2025, with the U.S. relapsed/refractory AL Amyloidosis patient population estimated at approximately 37,270 patients in 2025 and growing at 12% per year.
Oct 6, 2025, 8:05 PM
Immix Biopharma to Present at 37th Annual Piper Sandler Healthcare Conference
IMMX
New Projects/Investments
Product Launch
- Immix Biopharma, a clinical-stage biopharmaceutical company, will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference from December 2-4, 2025.
- The company's lead candidate, NXC-201, a BCMA-targeted CAR-T cell therapy, is being evaluated in the U.S. multi-center study NEXICART-2 for relapsed/refractory AL Amyloidosis.
- The primary endpoint for NEXICART-2 was met at interim results presented at ASCO 2025.
- NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by the FDA and in the EU by the EMA.
Oct 1, 2025, 12:45 PM
Immix Biopharma Announces Nancy T. Chang Joins Board of Directors
IMMX
Board Change
New Projects/Investments
- Nancy T. Chang, former Tanox, Inc. CEO and a proven biotechnology leader, has joined the Immix Biopharma Board of Directors.
- Dr. Chang's prior achievements include leading the development of FDA-approved XOLAIR®, TROGARZO®, and EBGLYSS®, which have collectively generated over $5 billion in sales.
- Her appointment coincides with her investment as a founding member of Goose Capital.
- Immix Biopharma is a clinical-stage biopharmaceutical company focused on cell therapies, with its lead candidate NXC-201 in a U.S. multi-center study for relapsed/refractory AL Amyloidosis.
Sep 11, 2025, 1:17 PM
Immix Biopharma Announces Strategy for Other Serious Diseases Programs
IMMX
New Projects/Investments
- Immix Biopharma (IMMX) announced its strategy to address Other Serious Diseases (OSD) with its NXC-201 CAR-T cell therapy, planning to partner-out these OSD programs through external partnerships.
- The company's primary focus remains on completing the NEXICART-2 study for NXC-201 in relapsed/refractory AL Amyloidosis for Biologics License Application (BLA) submission.
- These partnerships are expected to fuel the path to NEXICART-2 BLA submission for FDA approval and future development programs.
Aug 6, 2025, 4:30 PM
Immix Biopharma Announces NXC-201 Safety Profile and BLA Progress
IMMX
Product Launch
New Projects/Investments
- Immix Biopharma announced a class-leading safety profile for its CAR-T therapy NXC-201, including the absence of neurotoxicity in low-volume disease, which supports potential future indication expansion.
- The company is on track for the first Biologics License Application (BLA) approved cell therapy in the orphan indication relapsed/refractory AL Amyloidosis, with near-term efforts focused on NEXICART-2 BLA submission for FDA approval.
- NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation (ODD) from the US FDA, and ODD from the EMA.
- The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated at 33,277 patients in 2024, with the overall Amyloidosis market projected to reach $6 billion in 2025.
Jul 11, 2025, 1:36 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more